Dividend Contrast: Pfizer Defends 6.75% Yield Amid COVID Decline as Merck Eyes Pipeline
Recent quarterly reports show Pfizer and Merck diverging in strategy, with Pfizer focusing on dividend defense and Merck prioritizing pipeline expansion. While Pfizer manages a steep decline in COVID-related revenue, Merck is absorbing multi-billion dollar acquisition charges to prepare for future p
Key takeaways
- Pfizer is maintaining a high dividend yield of 6.75% while pivoting away from its declining COVID-19 product portfolio.
- Merck is prioritizing aggressive acquisitions to diversify its revenue streams before the Keytruda patent cliff arrives.
- Pfizer has secured a patent extension for Vyndamax until 2031, providing significant protection for its dividend coverage.
- Merck's financial results were impacted by substantial deal charges, including a $9 billion acquisition cost for Cidara.
What Happened
Pharmaceutical giants Pfizer and Merck released updated financial results, highlighting distinct capital allocation priorities. Pfizer reported quarterly revenue of $14.45 billion, exceeding estimates despite a 59% drop in Comirnaty sales and a 62% decline in Paxlovid revenue. The company maintains a dividend yield of approximately 6.75%, paying out $2.4 billion in the March quarter. Adjusted earnings per share reached $0.75, representing a fifth consecutive beat even as net income decreased by 9.44%.
Merck reported $16.29 billion in revenue, driven by Keytruda, which generated $8.03 billion. However, Merck reported a quarterly loss with an EPS of -$1.28, primarily due to a $9 billion charge related to the Cidara acquisition. The company also saw a 19% decline in Gardasil sales following the conclusion of a catch-up program in China.
Background
Pfizer is navigating a significant transition as the demand for pandemic-era products fades. To offset this runoff, the company is relying on growth from launched or acquired products, which saw 22% operational growth. Key performers include Padcev, which rose 39% to $591 million, and Eliquis, which grew 13% to $2.17 billion. A patent settlement for Vyndamax has extended its U.S. exclusivity to June 2031, providing a stabilized revenue stream to support dividend obligations.
Merck is currently focused on diversifying its portfolio ahead of the patent cliff for Keytruda later this decade. The company has engaged in several acquisitions, including Verona Pharma and Terns, to broaden its therapeutic reach. Interest expenses for Merck have increased from $313 million to $479 million as it leverages capital for these deals.
What Happens Next
For Pfizer, the year 2026 will be a critical period for pipeline development. The company anticipates running approximately 20 pivotal trials, with 10 resulting from the Metsera obesity acquisition. Management has specifically identified oncology and obesity as the primary sectors for future leadership. Pfizer has also confirmed it will not conduct stock buybacks in 2026, prioritizing the dividend and debt management.
Merck has raised its annual revenue guidance to a range of $65.8 billion to $67 billion. The company's future performance will depend on the adoption of the subcutaneous version of Keytruda, known as Keytruda QLEX, and the market ramp-up of Winrevair, which recently saw an 88% surge in revenue to $525 million.
Key Facts
- Pfizer currently offers a 6.75% dividend yield with an annual payout of $1.72 per share.
- Merck's dividend yield sits at 2.6% following a quarterly increase to $0.85 per share.
- Pfizer's COVID-related products, Comirnaty and Paxlovid, saw revenue declines of 59% and 62% respectively.
- Merck absorbed a $9 billion acquisition charge for Cidara, contributing to a reported EPS loss of $1.28.
- Pfizer's Vyndamax patent exclusivity is secured until June 2031.
- Merck's Keytruda QLEX recorded $128 million in its initial market entry.
Sources reviewed
Project Chintan independently synthesized and analyzed information cross-checked across the sources listed above.
Related stories
ESPN Begins Broad Regional Coverage for 2026 Little League World Series Qualifying
Arsenal Weighs Martinelli Exit as Galatasaray Submits Transfer Bid
Oxford United Exit League Cup as Southampton Supporters Receive Bans for Play-Off Conduct
